Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 3Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 20Bevacizumab 14Carboplatin 12Standard of Care 10Nivolumab 9Cyclophosphamide 9Cetuximab 8Pemetrexed 7Exercise 7Doxorubicin 7durvalumab 6atezolizumab 6Temozolomide 6Radiotherapy 6Prednisone 6Paclitaxel 6Cisplatin 6Blood Specimen Collection 6abemaciclib 5Fluorouracil 5130-nm albumin-bound paclitaxel 5olaparib 4dostarlimab 4Rituximab 4Leucovorin 4Gemcitabine 4Fulvestrant 4Docetaxel 4Dexamethasone 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Hyaluronoglucosaminidase × 30 days × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡